Thomas Bologna, Chief Executive Officer, Orchid Cellmark Inc.

Thomas Bologna successfully led the health care divisions of public, Fortune 500 and venture-backed biotechnology companies. A leader in the osteoporosis market, he was one of the first chief executive officers (CEOs) to model ‘companion diagnostics’ with a pharmaceutical product. Mr. Bologna is president and CEO of Orchid Cellmark Inc. (NASDAQ: ORCH), an international company that provides DNA identity testing services to the forensic and paternity markets.

Mr. Bologna served as president and CEO of Quorex Pharmaceuticals Inc., a venture-backed company purchased by Pfizer Inc.; chairman of the board, president and CEO of Ostex International Inc., purchased by Inverness Medical Innovations; and president and CEO of Scriptgen Pharmaceuticals, a Boston biotechnology start-up.

Mr. Bologna began his career began as president, CEO and chairman of the board of Gen-Probe Inc., a leading clinical diagnostics DNA-probe company that successfully commercialized products for the identification of infectious diseases. Gen-Probe flourished under his leadership, and was made public on the NASDAQ before being sold to Chugai Pharmaceutical Co. Ltd. Mr. Bologna also served as president of Becton Dickinson’s Diagnostic Systems Division and vice president at the Warner Lambert Company (now Pfizer).

Charles Cahn, Chief Executive Officer, Cahn Medical Technologies

Charles Cahn, head of Cahn Medical Technologies (CMT), invests in and manages start-up medical technology companies. He serves as board chairman of TyRx Pharma Inc., a surgical infection control company; board chairman of MicroMRI Inc., an MRI-based imaging company focused on osteoporosis assessment; a member of the board of Cylex; and chief executive officer of Calretex LLC, a wound management company.

As senior vice president at Sanford C. Bernstein & Co., an independent research and management firm, Mr. Cahn served on the board of directors and as senior managing director of the group’s research business. Alliance Capital Management purchased the company in 2000.

Mr. Cahn serves on the boards of companies invested in by CMT; SCB Inc., the advisory board of the Sanford C. Bernstein & Co. Center on Leadership and Ethics, at the Columbia Business School; and CEI-PEA (Center for Educational Innovation – Public Education Association). He chairs the board of the Cahn Fellows Program for Distinguished New York City Principals at Teachers College, Columbia University. Mr. Cahn graduated from Washington and Lee University and holds a masters of business administration from Columbia University.

Ronald Hahn, General Partner, Battelle Ventures

Ronald Hahn invests in and works closely with early-stage businesses. His current activity, highlighting a three-decade career, focuses on health care and life science technologies. Mr. Hahn serves as a member of the board of Cylex, and director of BacTalk LLC, Lotus Separations LLC and Panomics Inc.

Mr. Hahn is an adjunct professor of finance at the Columbia Business School. He received a bachelor’s degree from Occidental College, and a masters of business administration from the University of California, Los Angeles.

Tracy Marshbanks, Ph.D., Managing Director, First Analysis

As managing director, Dr. Tracy Marshbanks coordinates investment and research activities in the chemistry-enabled sector. Prior to joining First Analysis in 1999, he performed economic and strategic analysis of retail facility placement, acquisition and divestment for Amoco Corp. There, Dr. Marshbanks refined capital planning and worked as a research engineer.

Dr. Marshbanks earned his doctorate in chemical engineering from Purdue University, a masters of business administration from the University of Chicago, and a bachelor's degree in chemical engineering from Colorado State University.

Seth Rudnick, M.D., General Partner, Canaan Partners

A health care industry pioneer, Dr. Seth Rudnick founded and led several start-up companies to success. His comprehensive experience includes research, development, clinical trial analysis and biotechnology. Rudnick joined Canaan in 1998, and currently sits on the boards of Adlyfe, Chimerix, Cylex, Orthocon, Sopherion, Spine Wave and VaxInnate. He served as chief executive officer and chairman at CytoTherapeutics.

Dr. Rudnick was co-founder, and served as head of research and development, for Ortho Biotech, a division of Johnson & Johnson. In that role, he led development efforts for a portfolio of projects that continue to generate significant revenues for the company. He began his industrial career at Schering-Plough, where he ran clinical trials for the alpha interferon project; he later transferred to Biogen, managing that company's pharmaceutical development efforts.

Dr. Rudnick serves on the medical and public health faculty at Chapel Hill, where he is a clinical professor of medicine and advises faculty on biotechnology issues.

Carol Winslow, Founder and Principal, Channel Medical Partners

Carol Winslow is a veteran of more than 25 years in the medical technology industry, devoting much of that time to developing expertise in private and public medical technology investment.

Prior to founding Channel Medical Partners, she served as senior medical device analyst – responsible for equity research activities within the medical technology industry – at Jeffries & Company Inc., Vector Securities International Inc., and Dain Bosworth Incorporated. Ms. Winslow held management positions with Medtronic Inc. She serves on the board of directors of several private medical technology companies in Channel’s investment portfolio and the non-profit American Refugee Committee.

Ms. Winslow received her bachelor’s degree from Mount Holyoke College and a masters of business administration from the University of Minnesota.